 - Histologically confirmed CD30 classical HL central pathology review; results not required to enroll the patient in the study, primarily refractory to first line chemotherapy or in first relapse after any polychemotherapy regimen e.g. ABVD Adriamycin, bleomycin, vinblastine, and dacarbazine, baseline BEACOPP bleomycin, etoposide, Adriamycin, cyclophosphamide, Oncovin, procarbazine, and prednisone or escalated BEACOPP, or other induction regimens 